Search

Your search keyword '"Gatt, Moshe"' showing total 553 results
Start Over Author "Gatt, Moshe"
553 results on '"Gatt, Moshe"'

1. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma

Author

Kfir-Erenfeld, Shlomit, Asherie, Nathalie, Lebel, Eyal, Vainstein, Vladimir, Assayag, Miri, Dubnikov Sharon, Tatyana, Grisariu, Sigal, Avni, Batia, Elias, Shlomo, Alexander-Shani, Rivka, Bessig, Nomi, Shehadeh, Alaa, Ishtay, Aseel, Zelmanovich, Veronica, Zimran, Eran, Pick, Marjorie, Roziner, Ilan, Kenett, Ron S., Cohen, Yael, Avivi, Irit, Cohen, Cyrille J., Gatt, Moshe E., and Stepensky, Polina

Published
2024
Full Text
View/download PDF

4. Lymphoid Leukemias

Author

Elitzur, Sarah, primary, Izraeli, Shai, additional, Ben-Yehuda, Dina, additional, and Gatt, Moshe E., additional

Published
2023
Full Text
View/download PDF

5. List Of Contributors

Author

Abraham, Roshini Sarah, primary, Afzali, Behdad, additional, Águeda, Ana, additional, Akin, Cem, additional, Albanesi, Cristina, additional, Antiochos, Brendan, additional, Aranow, Cynthia, additional, Atkinson, John P., additional, Aune, Thomas M., additional, Babu, Subash, additional, Balko, Justin, additional, Ballow, Mark, additional, Bean, Rachel, additional, Belavgeni, Alexia, additional, Berek, Claudia, additional, Beukelman, Timothy, additional, Beziat, Vivien, additional, Bimler, Lynn, additional, Andrew Bird, J., additional, Blutt, Sarah E., additional, Boguniewicz, Mark, additional, Boisson, Bertrand, additional, Boisson-Dupuis, Stéphanie, additional, Borzova, Elena, additional, Bottazzi, Maria, additional, Boyaka, Prosper N., additional, Bridges, John, additional, Browne, Sarah K., additional, Burks, A. Wesley, additional, Bustamante, Jacinta, additional, Casanova, Jean-Laurent, additional, Chan, Alice, additional, Chan, Edwin S.L., additional, Chatham, Walter Winn, additional, Chinen, Javier, additional, Christopher-Stine, Lisa, additional, Coates, Emily, additional, Cope, Andrew P., additional, Corry, David B., additional, Cosme, Joana, additional, Cron, Randy Q., additional, Dalakas, Marinos C., additional, Dann, Sara M., additional, Das, Satya, additional, Daughety, Molly M., additional, Diamond, Betty, additional, Dispenzieri, Angela, additional, Durham, Stephen R., additional, Eagar, Todd N., additional, Al-Hosni, Michelle, additional, Elitzur, Sarah, additional, Elmets, Craig A., additional, Erkan, Doruk, additional, Fleisher, Thomas A., additional, Fonacier, Luz, additional, Fontenot, Andrew P., additional, Fragoulis, George, additional, Francischetti, Ivo M.B., additional, Freiwald, Tilo, additional, Frew, Anthony J., additional, Fujihashi, Kohtaro, additional, Gadina, Massimo, additional, Gapin, Laurent, additional, Gatt, Moshe E., additional, Gershwin, M. Eric, additional, Gillespie, Susan L., additional, Gordon, Lynn K., additional, Goronzy, Jörg J., additional, Grattan, Clive E., additional, Greenspan, Neil S., additional, Gschwend, Anna, additional, Gustafson, Claire E., additional, Hackett, Tillie-Louise, additional, Hamilton, Robert G., additional, Happe, Myra, additional, Harrison, Leonard C., additional, Helbling, Arthur, additional, Heckmann, Emmaline, additional, Hogquist, Kristin, additional, Hohl, Tobias M., additional, Holland, Steven M., additional, Hotez, Peter J., additional, Houser, Katherine, additional, Huntingdon, Nicholas D., additional, Hwangpo, Tracy, additional, Izraeli, Shai, additional, Jaffe, Elaine S., additional, Jalkanen, Sirpa, additional, Java, Anuja, additional, Johnson, Douglas B., additional, Johnson, Tory, additional, Jordan, Michael B., additional, Joshi, Shyam R., additional, Jouanguy, Emmanuelle, additional, Kaminski, Henry J., additional, Kaufmann, Stefan H.E., additional, Khan, David A., additional, Kheradmand, Farrah, additional, Khokar, Dilawar Singh, additional, Khoury, Paneez, additional, Klein, Bruce S., additional, Klion, Amy D., additional, Kohn, Donald B., additional, Kono, Michihito, additional, Korngold, Robert, additional, Koulouri, Vasiliki, additional, Kuhns, Douglas B., additional, Kulkarni, Hrishikesh S., additional, Kuo, Caroline Y., additional, Kusner, Linda L., additional, Lahouti, Arash, additional, Lane, Laura C., additional, Laurence, Arian, additional, Lee, Joyce S., additional, Lee, S. Thera, additional, Leung, Donald Y.M., additional, Levy, Ofer, additional, Lewis, Dorothy E., additional, Li, Evan, additional, Libby, Peter, additional, Lichtman, Andrew H., additional, Linkermann, Andreas, additional, Lionakis, Michail S., additional, Liszewski, M. Kathryn, additional, Lockshin, Michael D., additional, Priel, Debra Long, additional, Lorenz, Adi Zoref, additional, Ludwig, Ralf J., additional, Luong, Amber, additional, Luqmani, Raashid Ahmed, additional, Mackay, Meggan, additional, Mahr, Alfred, additional, Malley, Tamir, additional, Mannon, Elinor C., additional, Mannon, Peter J., additional, Mannon, Roslyn B., additional, Manns, Michael P., additional, Maresso, Anthony, additional, Matson, Scott M., additional, Mavragani, Clio P., additional, Maynard, Craig L., additional, McDonald, Douglas, additional, Meylan, Françoise, additional, Miller, Stephen D., additional, Mitchell, Anna L., additional, Monos, Dimitri S., additional, Mueller, Scott N., additional, Mulders-Manders, Catharina M., additional, Munshi, Pashna N., additional, Murphy, Philip M., additional, Noel, Pierre, additional, Notarangelo, Luigi D., additional, Nunes-Santos, Cristiane J., additional, Nussbaum, Robert L., additional, Nutman, Thomas B., additional, Nutt, Stephen L., additional, O'Neill, Lorraine, additional, O'Shea, John J., additional, Ortel, Thomas L., additional, Pai, Sung-Yun, additional, Paul, Mary E., additional, Pearce, Simon, additional, Peterson, Erik J., additional, Pittaluga, Stefania, additional, Polverino, Francesca, additional, Puck, Jennifer M., additional, Puel, Anne, additional, Radbruch, Andreas, additional, Rajalingam, Raja, additional, Reece, Stephen T., additional, Reveille, John D., additional, Rich, Robert R., additional, Ridley, Lauren K., additional, Romeo, Andrew R., additional, Rooney, Cliona M., additional, Rosen, Antony, additional, Rosenzweig, Sergio, additional, Rouse, Barry T., additional, Rowley, Scott D., additional, Sahiner, Umit Murat, additional, Sakaguchi, Shimon, additional, Salinas, Whitney, additional, Salmi, Marko, additional, Satola, Sarah, additional, Schechter, Marcos, additional, Schmidt, Enno, additional, Schroeder, Harry W., additional, Schwartzberg, Pamela L., additional, Sciumè, Giuseppe, additional, Segal, Benjamin M., additional, Selmi, Carlo, additional, Sharabi, Amir, additional, Shimano, Kristin Ammon, additional, Sikorski, Patricia M., additional, Simon, Anna, additional, Smith, Gideon P., additional, Song, Joo Y., additional, Stephens, David S., additional, Stephens, Robin, additional, Sun, Michel M., additional, Beretta-Piccoli, Benedetta Terziroli, additional, Tonnus, Wulf, additional, Torgerson, Troy R., additional, Torres, Raul Martin, additional, Treat, Jennifer D., additional, Tsokos, George C., additional, Uzel, Gülbü, additional, Uzonna, Jude E., additional, van der Hilst, Jeroen C.H., additional, van der Meer, Jos W.M., additional, Varga, John, additional, Waldman, Meryl, additional, Weatherhead, Jill, additional, Weiser, Peter, additional, Weyand, Cornelia M., additional, Wigley, Fredrick M., additional, Wing, James B., additional, Wood, Kathryn J., additional, Wilde, Shyra, additional, Xu, Hui, additional, Yusuf, Nabiha, additional, Zerbe, Christa S., additional, Zhang, Qian, additional, Ben-Yehuda, Dina, additional, Zhang, Shen-Ying, additional, and Zieske, Arthur W., additional

Published
2023
Full Text
View/download PDF

8. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Author

Schjesvold, Fredrik, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Nikolayeva, Anna, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Maisnar, Vladimir, Mikala, Gabor, Rosinol, Laura, Konstantinova, Tatiana, Lazzaro, Antonio, Liberati, Anna Marina, Symeonidis, Anargyros, Gatt, Moshe, Illes, Arpad, Abdulhaq, Haifaa, Dungarwalla, Moez, Grosicki, Sebastian, Hajek, Roman, Leleu, Xavier, Myasnikov, Alexander, Richardson, Paul G., Avivi, Irit, Deeren, Dries, Gironella, Mercedes, Hernandez-Garcia, Miguel Teodoro, Martinez Lopez, Joaquin, Newinger-Porte, Muriel, Ribas, Paz, Samoilova, Olga, Voog, Eric, Arnao-Herraiz, Mario, Carrillo-Cruz, Estrella, Corradini, Paolo, Dodlapati, Jyothi, Granell Gorrochategui, Miquel, Huang, Shang-Yi, Jenner, Matthew, Karlin, Lionel, Kim, Jin Seok, Kopacz, Agnieszka, Medvedeva, Nadezhda, Min, Chang-Ki, Mina, Roberto, Palk, Katrin, Shin, Ho-Jin, Sohn, Sang Kyun, Sonneveld, Pieter, Tache, Jason, Anagnostopoulos, Achilles, Arguiñano, Jose-Maria, Cavo, Michele, Filicko, Joanne, Garnes, Margaret, Halka, Janusz, Herzog-Tzarfati, Kathrin, Ipatova, Natalia, Kim, Kihyun, Krauth, Maria-Theresa, Kryuchkova, Irina, Lazaroiu, Mihaela Cornelia, Luppi, Mario, Proydakov, Andrei, Rambaldi, Alessandro, Rudzianskiene, Milda, Yeh, Su-Peng, Alcalá-Peña, Maria Magdalena, Alegre Amor, Adrian, Alizadeh, Hussain, Bendandi, Maurizio, Brearton, Gillian, Brown, Randall, Cavet, Jim, Dally, Najib, Egyed, Miklos, Hernández-Rivas, José Ángel, Kaare, Ain, Karsenti, Jean-Michel, Kloczko, Janusz, Kreisle, William, Lee, Je-Jung, Legiec, Wojciech, Machherndl-Spandl, Sigrid, Manda, Sudhir, Mateos, Maria-Victoria, Moiseev, Ivan, Moreb, Jan, Nagy, Zsolt, Nair, Santosh, Oriol-Rocafiguera, Albert, Osswald, Michael, Otero-Rodriguez, Paula, Peceliunas, Valdas, Plesner, Torben, Rey, Philippe, Rossi, Giuseppe, Stevens, Don, Suriu, Celia, Tarella, Corrado, Verlinden, Anke, Zannetti, Alain, Schjesvold, Fredrik H, Pour, Luděk, Špička, Ivan, Mikala, Gábor, Rosiñol, Laura, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, and Richardson, Paul G

Published
2022
Full Text
View/download PDF

9. Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.

Author

Itchaki, Gilad, Jarhovsky, Osnat, Castillo, Jorge J., Hassan, Hamza, Gatt, Moshe L., Leiba, Merav, Raanani, Pia, Gertz, Morie A., and Vaxman, Iuliana

Subjects
LITERATURE reviews, MULTIPLE myeloma, ISRAEL-United States relations, WALDENSTROM'S macroglobulinemia, PLASMA cells
Abstract

The simultaneous occurrence of Waldenström macroglobulinemia and multiple myeloma in the same patient has been published as case reports. Patients with Waldenström macroglobulinemia often have a small clone of plasma cells. However, the concurrent occurrence of symptomatic myeloma with lytic bone lesions is rare. The diagnosis of this 'hybrid' entity is challenging, and there are no standard therapies. We present six patients from five centers (three in Israel and two in the United States). We describe these patients' unique clinical course and treatment approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Author

Cohen, Yael C., Zada, Mor, Wang, Shuang-Yin, Bornstein, Chamutal, David, Eyal, Moshe, Adi, Li, Baoguo, Shlomi-Loubaton, Shir, Gatt, Moshe E., Gur, Chamutal, Lavi, Noa, Ganzel, Chezi, Luttwak, Efrat, Chubar, Evgeni, Rouvio, Ory, Vaxman, Iuliana, and Pasvolsky, Oren

Subjects
Oncology, Experimental, Molecular dynamics -- Research, Drug resistance -- Research, Multiple myeloma -- Drug therapy -- Patient outcomes, Cancer -- Relapse -- Research, Biological sciences, Health
Abstract

Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity within and between treatment-resistant patients is poorly characterized. In the present study, we conduct a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) to study the molecular dynamics of MM resistance mechanisms. Newly diagnosed MM patients (41), who either failed to respond or experienced early relapse after a bortezomib-containing induction regimen, were enrolled to evaluate the safety and efficacy of a daratumumab, carfilzomib, lenalidomide and dexamethasone combination. The primary clinical endpoint was safety and tolerability. Secondary endpoints included overall response rate, progression-free survival and overall survival. Treatment was safe and well tolerated; deep and durable responses were achieved. In prespecified exploratory analyses, comparison of 41 primary refractory and early relapsed patients, with 11 healthy subjects and 15 newly diagnosed MM patients, revealed new MM molecular pathways of resistance, including hypoxia tolerance, protein folding and mitochondria respiration, which generalized to larger clinical cohorts (CoMMpass). We found peptidylprolyl isomerase A (PPIA), a central enzyme in the protein-folding response pathway, as a potential new target for resistant MM. CRISPR-Cas9 deletion of PPIA or inhibition of PPIA with a small molecule inhibitor (ciclosporin) significantly sensitizes MM tumor cells to proteasome inhibitors. Together, our study defines a roadmap for integrating scRNA-seq in clinical trials, identifies a signature of highly resistant MM patients and discovers PPIA as a potent therapeutic target for these tumors. Integration of longitudinal single-cell analysis of relapsed and refractory multiple myeloma patients in a prospective clinical trial uncovers new pathways of drug resistance and identifies potential actionable targets., Author(s): Yael C. Cohen [sup.1] [sup.2] , Mor Zada [sup.1] [sup.3] , Shuang-Yin Wang [sup.3] , Chamutal Bornstein [sup.3] , Eyal David [sup.3] , Adi Moshe [sup.3] , Baoguo Li [...]

Published
2021
Full Text
View/download PDF

14. Immune Therapies in AL Amyloidosis—A Glimpse to the Future.

Author

Haran, Arnon, Vaxman, Iuliana, Gatt, Moshe E., and Lebel, Eyal

Subjects
AMYLOIDOSIS treatment, THERAPEUTIC use of monoclonal antibodies, SYNDROMES, NEUROTOXICOLOGY, IMMUNOGLOBULIN light chains, IMMUNOTHERAPY, CYTOKINE release syndrome, BIOTHERAPY
Abstract

Simple Summary: Light-chain (AL) amyloidosis is a rare disease similar to the more common disease, multiple myeloma (MM). Both are caused by proliferation of malignant plasma cells. In AL amyloidosis, disease is a result of the deposition of aggregates of proteins, namely immunoglobulin light chains, secreted by the malignant plasma cells, in target organs such as the heart or kidneys. Historically, treatment of AL amyloidosis has followed that of MM. A wide range of novel immunotherapies, i.e., therapies which utilize or activate immune mechanisms to eliminate the disease, are already established in MM and are gradually being adopted in AL amyloidosis as well. Although promising, the increased frailty of typical AL amyloidosis compared to MM patients is a concern in the administration of these therapies, which may be associated with severe side effects. We review both the promise and the challenges with the expansion of MM immunotherapies to AL amyloidosis. Light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains in target organs, leading to multi-organ dysfunction. Treatment approaches have historically mirrored but lagged behind those of multiple myeloma (MM). Recent advancements in MM immunotherapy are gradually being evaluated and adopted in AL amyloidosis. This review explores the current state of immunotherapeutic strategies in AL amyloidosis, including monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapy. We discuss the unique challenges and prospects of these therapies in AL amyloidosis, including the exposure of frail AL amyloidosis patients to immune-mediated toxicities such as cytokine release syndrome (CRS) and immune effector-cell-associated neurotoxicity syndrome (ICANS), as well as their efficacy in promoting rapid and deep hematologic responses. Furthermore, we highlight the need for international initiatives and compassionate programs to provide access to these promising therapies and address critical unmet needs in AL amyloidosis management. Finally, we discuss future directions, including optimizing treatment sequencing and mitigating toxicities, to improve outcomes for AL amyloidosis patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. OA-34 Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis

Author

Lebel, Eyal, primary, Kfir-erenfeld, Shlomit, additional, Asherie, Nathalie, additional, Grisariu, Sigal, additional, Avni, Batia, additional, Elias, Shlomo, additional, Assayag, Miri, additional, Dubnikov, Tatyana, additional, Zalcman, Nomi, additional, Pick, Marjorie, additional, Zimran, Eran, additional, Shaulov, Adir, additional, Cohen, Yaël, additional, Avivi, Irit, additional, Cohen, Cyrille, additional, Stepensky, Polina, additional, and Gatt, Moshe, additional

Published
2023
Full Text
View/download PDF

21. P-026 Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma

Author

Lebel, Eyal, primary, Kfir-erenfeld, Shlomit, additional, Asherie, Nathalie, additional, Grisariu, Sigal, additional, Avni, Batia, additional, Elias, Shlomo, additional, Assayag, Miri, additional, Dubnikov, Tatyana, additional, Zalcman, Nomi, additional, Pick, Marjorie, additional, Zimran, Eran, additional, Shaulov, Adir, additional, Cohen, Yaël, additional, Avivi, Irit, additional, Cohen, Cyrille, additional, Stepensky, Polina, additional, and Gatt, Moshe, additional

Published
2023
Full Text
View/download PDF

22. MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Cohen, Yael, primary, Morillo, Daniel, additional, Gatt, Moshe, additional, Sebag, Michael, additional, Kim, Kihyun, additional, Min, Chang-Ki, additional, Oriol, Albert, additional, Ocio, Enrique, additional, Yoon, Sung-Soo, additional, Mateos, Maria-Victoria, additional, Chu, Michael, additional, Rodriguez-Otero, Paula, additional, Avivi, Irit, additional, Guo, Yue, additional, Krevvata, Maria, additional, Peterson, Michelle, additional, Beelen, Melissa, additional, Vanak, Jill, additional, Banerjee, Arnob, additional, and Magen, Hila, additional

Published
2023
Full Text
View/download PDF

23. P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Author

Magen, Hila, primary, Morillo, Daniel, additional, Gatt, Moshe, additional, Sebag, Michael, additional, Kim, Kihyun, additional, Min, Chang-Ki, additional, Oriol, Albert, additional, Ocio, Enrique, additional, Yoon, Sung-Soo, additional, Mateos, Maria-Victoria, additional, Chu, Michael, additional, Rodriguez-Otero, Paula, additional, Avivi, Irit, additional, Guo, Yue, additional, Krevvata, Maria, additional, Peterson, Michelle, additional, Beelen, Melissa, additional, Vanak, Jill, additional, Banerjee, Arnob, additional, and Cohen, Yaël, additional

Published
2023
Full Text
View/download PDF

24. POSTER: MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Author

Richardson, Paul G., primary, Badelita, Sorina N., additional, Besemer, Britta, additional, Boudreault, Jean-Samuel, additional, Byun, Ja Min, additional, Cerchione, Claudio, additional, Gatt, Moshe E., additional, Gibbs, Simon, additional, Koroda, Junya, additional, Martinez-Lopez, Joaquín, additional, Min, Chang-Ki, additional, Orlowski, Robert Z., additional, Quach, Hang, additional, Raab, Marc S., additional, Weisel, Katja, additional, Zhou, Xin, additional, Amatangelo, Michael, additional, Wang, Yue, additional, Hwang, Soo Jeong, additional, Emerson, Joshua, additional, Koo, Phillip, additional, Rocci, Alberto, additional, and Katz, Jessica, additional

Published
2023
Full Text
View/download PDF

25. POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Cohen, Yael, primary, Morillo, Daniel, additional, Gatt, Moshe, additional, Sebag, Michael, additional, Kim, Kihyun, additional, Min, Chang-Ki, additional, Oriol, Albert, additional, Ocio, Enrique, additional, Yoon, Sung-Soo, additional, Mateos, Maria-Victoria, additional, Chu, Michael, additional, Rodriguez-Otero, Paula, additional, Avivi, Irit, additional, Guo, Yue, additional, Krevvata, Maria, additional, Peterson, Michelle, additional, Beelen, Melissa, additional, Vanak, Jill, additional, Banerjee, Arnob, additional, and Magen, Hila, additional

Published
2023
Full Text
View/download PDF

26. MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1

Author

Richardson, Paul G., primary, Badelita, Sorina N., additional, Besemer, Britta, additional, Boudreault, Jean-Samuel, additional, Byun, Ja Min, additional, Cerchione, Claudio, additional, Gatt, Moshe E., additional, Gibbs, Simon, additional, Koroda, Junya, additional, Martinez-Lopez, Joaquín, additional, Min, Chang-Ki, additional, Orlowski, Robert Z., additional, Quach, Hang, additional, Raab, Marc S., additional, Weisel, Katja, additional, Zhou, Xin, additional, Amatangelo, Michael, additional, Wang, Yue, additional, Hwang, Soo Jeong, additional, Emerson, Joshua, additional, Koo, Phillip, additional, Rocci, Alberto, additional, and Katz, Jessica, additional

Published
2023
Full Text
View/download PDF

28. S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Author

Mateos, Maria-Victoria, primary, Morillo, Daniel, additional, Gatt, Moshe, additional, Sebag, Michael, additional, Kim, Kihyun, additional, Min, Chang-Ki, additional, Oriol, Albert, additional, Ocio, Enrique, additional, Yoon, Sung-Soo, additional, Cohen, Yael, additional, Chu, Michael, additional, Rodríguez-Otero, Paula, additional, Avivi, Irit, additional, Guo, Yue, additional, Krevvata, Maria, additional, Peterson, Michelle, additional, Beelen, Melissa, additional, Vanak, Jill, additional, Banerjee, Arnob, additional, and Magen, Hila, additional

Published
2023
Full Text
View/download PDF

29. PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS

Author

Kastritis, Efstathios, primary, Matous, Jeffrey, additional, Berdeja, Jesus, additional, Abro, Emad, additional, Augustson, Bradley, additional, Perianes, Valentin Cabañas, additional, Cibeira, M. Theresa, additional, Cohen, Yael, additional, Fong, Michael, additional, Gatt, Moshe, additional, DE LA Calle, Veronica Gonzalez, additional, Kwok, Fiona, additional, Lavi, Noa, additional, Magen, Hila, additional, Oriol, Albert, additional, Palladini, Giovanni, additional, Stockerl-Goldstein, Keith, additional, Eves, Taylor, additional, Zheng, Cheng, additional, and Fiorino, Anthony, additional

Published
2023
Full Text
View/download PDF

30. P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY

Author

Lebel, Eyal, primary, Kastritis, Efstathios, additional, Palladini, Giovanni, additional, Milani, Paolo, additional, Theodorakakou, Foteini, additional, Aumann, Shlomzion, additional, Lavi, Noa, additional, Shargian, Liat, additional, Magen, Hila, additional, Cohen, Yael, additional, Gatt, Moshe, additional, and Vaxman, Iuliana, additional

Published
2023
Full Text
View/download PDF

31. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?

Author

Vainstein, Vladimir, primary, Avni, Batia, additional, Grisariu, Sigal, additional, Kfir-Erenfeld, Shlomit, additional, Asherie, Nathalie, additional, Nachmias, Boaz, additional, Auman, Shlomtzion, additional, Saban, Revital, additional, Zimran, Eran, additional, Assayag, Miri, additional, Filanovsky, Kalman, additional, Horowitz, Netanel A., additional, Lebel, Eyal, additional, Shaulov, Adir, additional, Gur, Michal, additional, Rosenbluh, Chaggai, additional, Krichevsky, Svetlana, additional, Stepensky, Polina, additional, and Gatt, Moshe E., additional

Published
2023
Full Text
View/download PDF

33. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Author

Ledergor, Guy, Weiner, Assaf, Zada, Mor, Wang, Shuang-Yin, Cohen, Yael C., Gatt, Moshe E., Snir, Nimrod, Magen, Hila, Koren-Michowitz, Maya, Herzog-Tzarfati, Katrin, Keren-Shaul, Hadas, Bornstein, Chamutal, Rotkopf, Ron, Yofe, Ido, David, Eyal, Yellapantula, Venkata, Kay, Sigalit, Salai, Moshe, Ben Yehuda, Dina, Nagler, Arnon, Shvidel, Lev, Orr-Urtreger, Avi, Halpern, Keren Bahar, Itzkovitz, Shalev, Landgren, Ola, San-Miguel, Jesus, Paiva, Bruno, Keats, Jonathan J., Papaemmanuil, Elli, Avivi, Irit, Barbash, Gabriel I., Tanay, Amos, and Amit, Ido

Published
2018
Full Text
View/download PDF

34. Amyloidogenic light chains impair plasma cell survival

Author

Pick, Marjorie, primary, Lebel, Eyal, additional, Elgavish, Sharona, additional, Benyamini, Hadar, additional, Nevo, Yuval, additional, Hertz, Rachel, additional, Bar-Tana, Jacob, additional, Rognoni, Paola, additional, Merlini, Giampaolo, additional, and Gatt, Moshe E., additional

Published
2023
Full Text
View/download PDF

35. Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA

Author

Hiayev, Stephany, primary, Shacham-Shmueli, Einat, additional, Berkovitch, Matitiahu, additional, Weiss, Ilana, additional, Ashkenazi, Shai, additional, Vexberg, Michal Hirsch, additional, Hershkowitz, Rami, additional, Gorelik, Einat, additional, Mayan, Haim, additional, Steinmetz, Yehudit, additional, Yanai, Noa Berar, additional, Schlissel, Orly, additional, Azem, Muhammad, additional, Gutgold, Neriya, additional, Shulman, Katerina, additional, Divinsky, Milly, additional, Yarom, Nirit, additional, Vishkautzan, Alla, additional, Ganzel, Chezi, additional, Gatt, Moshe E, additional, Arcavi, Lidia, additional, Marom, Eli, additional, Uziely, Biatrice, additional, Zevin, Shoshana, additional, Meirow, Hadar, additional, Luxenburg, Osnat, additional, and Ainbinder, Denize, additional

Published
2023
Full Text
View/download PDF

37. List of Contributors

Author

Abraham, Roshini Sarah, primary, Albanesi, Cristina, additional, Alevizos, Ilias, additional, Anguita, Juan, additional, Antiochos, Brendan, additional, Aranow, Cynthia, additional, Atkinson, John P., additional, Austin, Howard A., additional, Babu, Subash, additional, Ballow, Mark C., additional, Balow, James E., additional, Belmont, John W., additional, Berek, Claudia, additional, Beukelman, Timothy, additional, Bhavsar, Tapan, additional, Bird, J. Andrew, additional, Blutt, Sarah E., additional, Boguniewicz, Mark, additional, Bonamichi-Santos, Rafael, additional, Boisson, Bertrand, additional, Borzova, Elena, additional, Boyaka, Prosper N., additional, Boyce, Joshua, additional, Browne, Sarah K., additional, Burks, Wesley, additional, Bustamante, Jacinta, additional, Calder, Virginia L., additional, Campbell, Matthew, additional, Cardones, Adela Rambi G., additional, Casanova, Jean-Laurent, additional, Castells, Mariana, additional, Cavacini, Lisa A., additional, Chan, Edwin S.L., additional, Chaplin, David D., additional, Chatham, W. Winn, additional, Chen, Edward S., additional, Chinen, Javier, additional, Christopher-Stine, Lisa, additional, Ciancanelli, Michael, additional, Cope, Andrew P., additional, Corry, David B., additional, Crea, Filippo, additional, Cron, Randy Q., additional, Cuellar-Rodriguez, Jennifer M., additional, Dalakas, Marinos C., additional, Dann, Sara M., additional, Diamond, Betty, additional, Du, Terry W., additional, Dupuis-Boisson, Stéphanie, additional, Eagar, Todd N., additional, Elmets, Craig A., additional, Erkan, Doruk, additional, Fanning, Laura, additional, Fikrig, Erol, additional, Flego, Davide, additional, Fleisher, Thomas A., additional, Fonacier, Luz, additional, Fontenot, Andrew P., additional, Freeman, Alexandra F., additional, Frew, Anthony J., additional, Fujihashi, Kohtaro, additional, Gadina, Massimo, additional, Gatt, Moshe E., additional, Gershwin, M. Eric, additional, Gillespie, Susan L., additional, Goronzy, Jörg J., additional, Goswami, Sangeeta, additional, Grattan, Clive E.H., additional, Greenspan, Neil S., additional, Gupta, Sarthak, additional, Gustafson, Claire E., additional, Hall, Russell P., additional, Hamilton, Robert G., additional, Harrington, Laurie E., additional, Harrison, Leonard C., additional, Hasni, Sarfaraz A., additional, Helbling, Arthur, additional, Hester, Joanna, additional, Holland, Steven M., additional, Hourcade, Dennis, additional, Huntington, Nicholas D., additional, Hwangpo, Tracy, additional, Imboden, John B., additional, Issa, Fadi, additional, Izraeli, Shai, additional, Jaffe, Elaine S., additional, Jalkanen, Sirpa, additional, Jones, Stacie, additional, Jouanguy, Emmanuelle, additional, Kabbani, Sarah, additional, Kaufmann, Stefan H.E., additional, Kheradmand, Farrah, additional, Kohn, Donald B., additional, Korngold, Robert, additional, Kovalszki, Anna, additional, Kuhns, Douglas B., additional, Kulkarni, Hrishikesh, additional, Kuo, Caroline Y., additional, Lahouti, Arash, additional, Landgren, C. Ola, additional, Laurence, Arian, additional, Lee, Joyce S., additional, Lemière, Catherine, additional, Leung, Donald Y.M., additional, Levinson, Arnold I., additional, Levy, Ofer, additional, Lewis, Dorothy E., additional, Lin, Phoebe, additional, Linkermann, Andreas, additional, Liuzzo, Giovanna, additional, Lockshin, Michael D., additional, Lord, Allison K., additional, Lozier, Jay N., additional, Luong, Amber, additional, Luqmani, Raashid, additional, Mackay, Meggan, additional, Maltzman, Jonathan S., additional, Mannon, Peter J., additional, Manns, Michael P., additional, Martin, James G., additional, Maynard, Craig L., additional, McCash, Samual, additional, McDonald, Douglas R., additional, Melby, Peter C., additional, Miller, Stephen D., additional, Mitchell, Anna L., additional, Mohd-Zaki, Amirah, additional, Mold, Carolyn, additional, Moller, David R., additional, Monos, Dimitrios S., additional, Mueller, Scott N., additional, Mulders-Manders, Catharina M., additional, Mulligan, Mark J., additional, Müller, Ulrich R., additional, Munshi, Pashna N., additional, Murata, Kazunori, additional, Murphy, Philip M., additional, Navasa, Nicolás, additional, Noel, Pierre, additional, Notarangelo, Luigi D., additional, Nussbaum, Robert L., additional, Nutman, Thomas B., additional, Nutt, Stephen L., additional, Oliveira, João B., additional, Ortel, Thomas L., additional, O'Shea, John J., additional, Pai, Sung-Yun, additional, Pandit, Lavannya, additional, Paul, Mary E., additional, Pearce, Simon H.S., additional, Pedicino, Daniela, additional, Peterson, Erik J., additional, Picard, Capucine, additional, Pittaluga, Stefania, additional, Priel, Debra Long, additional, Puck, Jennifer, additional, Puel, Anne, additional, Radbruch, Andreas, additional, Reece, Stephen T., additional, Reveille, John D., additional, Rich, Robert R., additional, Roifman, Chaim M., additional, Rosen, Antony, additional, Rosenbaum, James T., additional, Rosenzweig, Sergio D., additional, Rouse, Barry T., additional, Rowley, Scott D., additional, Sakaguchi, Shimon, additional, Salmi, Marko, additional, Sant, Andrea J., additional, Satola, Sarah W., additional, Saw, Valerie, additional, Schechter, Marcos C., additional, Schroeder, Harry W., additional, Segal, Benjamin M., additional, Selmi, Carlo, additional, Shankar, Sushma, additional, Sharma, Anu, additional, Sharma, Padmanee, additional, Shearer, William T., additional, Siegel, Richard M., additional, Simon, Anna, additional, Smith, Gideon P., additional, Stephens, David S., additional, Stephens, Robin, additional, Straumann, Alex, additional, Teos, Leyla Y., additional, Timares, Laura, additional, Tonnus, Wulf, additional, Torres, Raul M., additional, Uzel, Gülbü, additional, van der Hilst, Jeroen C.H., additional, van der Meer, Jos W.M., additional, Varga, John, additional, Vyas, Jatin M., additional, Waldman, Meryl, additional, Weiser, Peter, additional, Weller, Peter F., additional, Weyand, Cornelia M., additional, Wigley, Fredrick M., additional, Winchester, Robert J., additional, Wing, James B., additional, Wood, Kathryn J., additional, Wu, Xiaobo, additional, Xu, Hui, additional, Yee, Cassian, additional, and Zhang, Shen-Ying, additional

Published
2019
Full Text
View/download PDF

38. Data from BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells

Author

Mani, Mala, primary, Carrasco, Daniel E., primary, Zhang, Yunyu, primary, Takada, Kohichi, primary, Gatt, Moshe E., primary, Dutta-Simmons, Jui, primary, Ikeda, Hiroshi, primary, Diaz-Griffero, Felipe, primary, Pena-Cruz, Victor, primary, Bertagnolli, Monica, primary, Myeroff, Lois L., primary, Markowitz, Sanford D., primary, Anderson, Kenneth C., primary, and Carrasco, Daniel R., primary

Published
2023
Full Text
View/download PDF

39. Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis

Author

Merlini, Giampaolo, primary, Sarosiek, Shayna, additional, Benevolo, Giulia, additional, Cao, Xinxin, additional, Dimopoulos, Meletios, additional, Garcia-Sanz, Ramon, additional, Gatt, Moshe E., additional, Fernandez de Larrea, Carlos, additional, San-Miguel, Jesus, additional, Treon, Steven P., additional, and Minnema, Monique C., additional

Published
2023
Full Text
View/download PDF

40. Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma

Author

Shamriz, Oded, primary, Parnasa, Elchanan, additional, Rubin, Limor, additional, Talmon, Aviv, additional, Ribak, Yaarit, additional, Lebel, Eyal, additional, Vainstein, Vladimir, additional, Aumann, Shlomzion, additional, Saban, Revital, additional, Gatt, Moshe E., additional, and Tal, Yuval, additional

Published
2023
Full Text
View/download PDF

41. Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality.

Author

Aumann, Shlomzion, Tsubary, Uria, Nachmias, Boaz, Ben Yehuda, Dina, Lavie, David, Goldschmidt, Neta, Vainstein, Vladimir, Libster, Diana, Saban, Revital, Shaulov, Adir, Israel, Sarah, Avni, Batia, Grisariu, Sigal, Bdolah‐Amram, Tali, Gatt, Moshe, and Zimran, Eran

Subjects
HEMATOLOGIC malignancies, COVID-19, DEATH rate, MONOCLONAL antibodies, HOSPITAL patients
Abstract

Background: Studies addressing coronavirus disease 2019 (COVID‐19) in patients with hematological malignancies have reported mortality rates of up to 40%; however, included predominantly hospitalized patients. Methods: During the first year of the pandemic, we followed adult patients with hematological malignancies treated at a tertiary center in Jerusalem, Israel, who contracted COVID‐19, with the aim of studying risk factors for adverse COVID‐19‐related outcomes. We used remote communication to track patients managed at home‐isolation, and patient questioning to assess the source of COVID‐19 infection, community versus nosocomial. Results: Our series included 183 patients, median age was 62.5 years, 72% had at least one comorbidity and 39% were receiving active antineoplastic treatment. Hospitalization, critical COVID‐19, and mortality rates were 32%, 12.6%, and 9.8%, respectively, remarkably lower than previously reported. Age, multiple comorbidities, and active antineoplastic treatment were significantly associated with hospitalization due to COVID‐19. Treatment with monoclonal antibodies was strongly associated with both hospitalization and critical COVID‐19. In older (≥60) patients not receiving active antineoplastic treatment, mortality, and severe COVID‐19 rates were comparable to those of the general Israeli population. We did not detect patients that contracted COVID‐19 within the Hematology Division. Conclusion: These findings are relevant for the future management of patients with hematological malignancies in COVID‐19‐affected regions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome

Author

Ofran, Yishai, Filanovsky, Kalman, Gafter-Gvili, Anat, Vidal, Liat, Aviv, Ariel, Gatt, Moshe E., Silbershatz, Itay, Herishanu, Yair, Arad, Ariela, Tadmor, Tamar, Dally, Najib, Nemets, Anatoly, Rouvio, Ory, Ronson, Aharon, Herzog-Tzarfati, Katrin, Akria, Luiza, Braester, Andrei, Hellmann, Ilana, Yeganeh, Shay, Nagler, Arnon, Leiba, Ronit, Mittelman, Moshe, and Merkel, Drorit

Published
2015
Full Text
View/download PDF

43. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Author

Cohen, Yael C, primary, Gatt, Moshe E, additional, Luttwak, Efrat, additional, Lavi, Noa, additional, Ganzel, Chezi, additional, Chubar, Evgeni, additional, Rouvio, Ory, additional, Vaxman, Iuliana, additional, Pasvolsky, Oren, additional, Ballan, Mouna, additional, Tadmor, Tamar, additional, Nemets, Anatoly, additional, Jarchowsky, Osnat, additional, Shvetz, Olga, additional, Shpilberg, Ofer, additional, Dally, Najib, additional, Leiba, Merav, additional, Weiner, Assaf, additional, Zada, Mor, additional, Wang, Shuang-Yin, additional, Gur, Chamutal, additional, Lowenton-Spier, Noa, additional, Goor-Porges, Liron, additional, Amit, Ido, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

47. A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Author

Cohen, Yael C, primary, Shragai, Tamir, additional, Lavi, Noa, additional, Vaxman, Iuliana, additional, Chubar, Evgeni, additional, Gatt, Moshe E, additional, Ganzel, Chezi, additional, Magen, Hila, additional, Luttwak, Efrat, additional, Lowenton-Spier, Noa, additional, Gez-Aaronson, Liron, additional, Melamed, Natan, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

49. Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results

Author

Asherie, Nathalie, primary, Kfir-Erenfeld, Shlomit, additional, Avni, Batia, additional, Assayag, Miri, additional, Dubnikov, Tatyana, additional, Zalcman, Nomi, additional, Lebel, Eyal, additional, Zimran, Eran, additional, Shaulov, Adir, additional, Pick, Marjorie, additional, Cohen, Yael, additional, Avivi, Irit, additional, Cohen, Cyrille, additional, Gatt, Moshe E., additional, Grisariu, Sigal, additional, and Stepensky, Polina, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results